Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.
Contact
C/o SGH Secretaries Limited
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,847.60 | 205.10 | -2.55% |
| CAC 40 | 7,241.48 | 357.50 | -4.70% |
| DAX 40 | 20,567.86 | 1,149.53 | -5.29% |
| Dow JONES (US) | 38,523.37 | 2,022.56 | -4.99% |
| FTSE 100 | 8,045.37 | 429.37 | -5.07% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 15,654.42 | 896.19 | -5.41% |
| Nikkei 225 | 33,780.58 | 955.35 | -2.75% |
| NZX 50 Index | 12,225.28 | 113.29 | -0.92% |
| S&P 500 | 5,097.32 | 299.20 | -5.54% |
| S&P/ASX 200 | 7,667.80 | 191.90 | -2.44% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |